 Connection
Paul Bunn to Cell Division
This is a "connection" page, showing publications Paul Bunn has written about Cell Division.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.369 |
|
|
|
-
Chan DC, Gera L, Stewart JM, Helfrich B, Zhao TL, Feng WY, Chan KK, Covey JM, Bunn PA. Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines in vitro and in vivo and produces synergistic growth inhibition in combination with other antitumor agents. Clin Cancer Res. 2002 May; 8(5):1280-7.
Score: 0.044
-
Chan D, Gera L, Stewart J, Helfrich B, Verella-Garcia M, Johnson G, Baron A, Yang J, Puck T, Bunn P. Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines by a "biased agonist" mechanism. Proc Natl Acad Sci U S A. 2002 Apr 02; 99(7):4608-13.
Score: 0.043
-
Chan DC, Earle KA, Zhao TL, Helfrich B, Zeng C, Baron A, Whitehead CM, Piazza G, Pamukcu R, Thompson WJ, Alila H, Nelson P, Bunn PA. Exisulind in combination with docetaxel inhibits growth and metastasis of human lung cancer and prolongs survival in athymic nude rats with orthotopic lung tumors. Clin Cancer Res. 2002 Mar; 8(3):904-12.
Score: 0.043
-
Shackney SE, Edelson R, Bunn PA. The kinetics of S?zary cell production. Cancer Treat Rep. 1979 Apr; 63(4):659-61.
Score: 0.035
-
Bunn PA, Helfrich BA, Brenner DG, Chan DC, Dykes DJ, Cohen AJ, Miller YE. Effects of recombinant neutral endopeptidase (EC 3.4.24.11) on the growth of lung cancer cell lines in vitro and in vivo. Clin Cancer Res. 1998 Nov; 4(11):2849-58.
Score: 0.034
-
Chan D, Gera L, Helfrich B, Helm K, Stewart J, Whalley E, Bunn P. Novel bradykinin antagonist dimers for the treatment of human lung cancers. Immunopharmacology. 1996 Jun; 33(1-3):201-4.
Score: 0.029
-
Bunn PA, Chan D, Dienhart DG, Tolley R, Tagawa M, Jewett PB. Neuropeptide signal transduction in lung cancer: clinical implications of bradykinin sensitivity and overall heterogeneity. Cancer Res. 1992 Jan 01; 52(1):24-31.
Score: 0.021
-
Bunn PA, Dienhart DG, Chan D, Tagawa M, Jewett P. Effects of neuropeptides on human lung and breast cancer cells. J Natl Cancer Inst Monogr. 1992; (13):145-51.
Score: 0.021
-
Beck LK, Kane MA, Bunn PA. Innovative and future approaches to small cell lung cancer treatment. Semin Oncol. 1988 Jun; 15(3):300-14.
Score: 0.017
-
Frederick BA, Helfrich BA, Coldren CD, Zheng D, Chan D, Bunn PA, Raben D. Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma. Mol Cancer Ther. 2007 Jun; 6(6):1683-91.
Score: 0.016
-
Whitehead CM, Earle KA, Fetter J, Xu S, Hartman T, Chan DC, Zhao TL, Piazza G, Klein-Szanto AJ, Pamukcu R, Alila H, Bunn PA, Thompson WJ. Exisulind-induced apoptosis in a non-small cell lung cancer orthotopic lung tumor model augments docetaxel treatment and contributes to increased survival. Mol Cancer Ther. 2003 May; 2(5):479-88.
Score: 0.012
-
Ahnen DJ, Feigl P, Quan G, Fenoglio-Preiser C, Lovato LC, Bunn PA, Stemmerman G, Wells JD, Macdonald JS, Meyskens FL. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res. 1998 Mar 15; 58(6):1149-58.
Score: 0.008
-
Beekman A, Helfrich B, Bunn PA, Heasley LE. Expression of catalytically inactive phospholipase Cbeta disrupts phospholipase Cbeta and mitogen-activated protein kinase signaling and inhibits small cell lung cancer growth. Cancer Res. 1998 Mar 01; 58(5):910-3.
Score: 0.008
-
Bunn PA, Ford SS, Shackney SE. Rapid grain and cell counting for cell kinetic studies. J Natl Cancer Inst. 1977 Jul; 59(1):285-7.
Score: 0.008
-
Franklin WA, Folkvord JM, Varella-Garcia M, Kennedy T, Proudfoot S, Cook R, Dempsey EC, Helm K, Bunn PA, Miller YE. Expansion of bronchial epithelial cell populations by in vitro culture of explants from dysplastic and histologically normal sites. Am J Respir Cell Mol Biol. 1996 Sep; 15(3):297-304.
Score: 0.007
-
Howard RB, Chu H, Zeligman BE, Marcell T, Bunn PA, McLemore TL, Mulvin DW, Cowen ME, Johnston MR. Irradiated nude rat model for orthotopic human lung cancers. Cancer Res. 1991 Jun 15; 51(12):3274-80.
Score: 0.005
-
Roth MS, Bunn PA, Foon KA. Interferon therapy for lymphoproliferative disorders. Cancer Treat Res. 1988; 38:231-52.
Score: 0.004
-
Sidi Y, Edwards NL, Winkler C, Bunn P, Mitchell BS. Differential metabolism of deoxyribonucleosides by leukaemic T cells of immature and mature phenotype. Br J Haematol. 1985 Sep; 61(1):125-34.
Score: 0.003
-
Carney DN, Bunn PA, Gazdar AF, Pagan JA, Minna JD. Selective growth in serum-free hormone-supplemented medium of tumor cells obtained by biopsy from patients with small cell carcinoma of the lung. Proc Natl Acad Sci U S A. 1981 May; 78(5):3185-9.
Score: 0.003
-
Carney DN, Bunn PA, Schechter GP, Gazdar AF. Lymphocyte transformation in patients with cutaneous T-cell lymphomas. Int J Cancer. 1980 Nov 15; 26(5):535-42.
Score: 0.002
-
Gazdar AF, Carney DN, Bunn PA, Russell EK, Jaffe ES, Schechter GP, Guccion JG. Mitogen requirements for the in vitro propagation of cutaneous T-cell lymphomas. Blood. 1980 Mar; 55(3):409-17.
Score: 0.002
-
Brigham BA, Bunn PA, Minna JD, Cohen MH, Ihde DC, Shackney SE. Growth rates of small cell bronchogenic carcinomas. Cancer. 1978 Dec; 42(6):2880-6.
Score: 0.002
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|